Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0132 Phase 3 Study in Dry Eye Disease
jRCT2031220497Phase 3Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye syndrome (DED) comparing SJP-0132 with Placebo (2 arms). Primary endpoint: Change from baseline in DEQS total score at Week 4. Started Jan 2023; status: completed.
02
Drugs
motsugibatorep
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on jRCT2031220497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220497.